2400001E08Rik Inhibitors belong to a specific chemical class of compounds that have been subject to scientific investigation for their potential to selectively modulate the activity of the 2400001E08Rik protein, also known as C20orf111. These inhibitors are thoughtfully designed to interact with specific regions or binding sites within the 2400001E08Rik protein, with the aim of influencing its functional activity. The study of 2400001E08Rik Inhibitors is of considerable interest due to the potential implications in understanding the biological functions and cellular processes associated with the C20orf111 protein. Through in-depth investigations, researchers seek to unravel the molecular mechanisms underlying 2400001E08Rik's involvement within cellular environments. Moreover, the exploration of these inhibitors offers valuable insights into the broader context of cellular signaling pathways and protein interactions, contributing to a deeper understanding of cellular processes that involve 2400001E08Rik.
It is essential to emphasize that the field of 2400001E08Rik Inhibitors is continuously evolving, and further research is required to fully elucidate the precise mechanisms of action and potential selectivity of these compounds for 2400001E08Rik. As with any active area of research, continued exploration of 2400001E08Rik Inhibitors holds promise in advancing our knowledge of the functions and significance of the C20orf111 protein, potentially opening new avenues for future investigations and uncovering novel biological roles. However, until more data becomes available, the full extent of the implications and potential applications of 2400001E08Rik Inhibitors remains to be elucidated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR (Epidermal Growth Factor Receptor) inhibitor. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor that targets BCR-ABL. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
A histone demethylase inhibitor. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-beta receptor. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
An NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) inhibitor. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
An antimetabolite used in chemotherapy. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
A platinum-based chemotherapy drug that forms DNA adducts. | ||||||